DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Omaxe Limited — Sale or disposal

NSE 2 hrs ago·1 Oct 2026, 12:45 pm

Omaxe

Omaxe Limited has informed the stock exchanges about the potential sale or disposal of its 40% stake in M/s Aquarise Developers Private Limited. This stake is currently held by Dinkar Realcon Private Limited, which is a step-down wholly-owned subsidiary of Omaxe.

This development is significant for investors as it signals a potential strategic shift or capital reallocation by the company. The move could indicate Omaxe's intention to monetize assets or focus on its core business operations, which may impact the company's financial structure and future growth prospects.

Investors should monitor the official announcement for further details regarding the transaction structure and the timing of the sale. The outcome of this move will be key to understanding Omaxe's future direction and its impact on the stock price.